Adrenal function under long-term raloxifene administration

References

• Jensen EV. Steroid hormones, receptors and antagonists. Ann NY Acad Sci 1996;784:1–17
   PubMed Web of Science ®Google Scholar
• Brzozowski AM, Pike ACW, Dauter Z, et al. Molecular basis of agonist and antagonist in the estrogen receptor. Nature (London) 1997;389: 753–8
   PubMed Web of Science ®Google Scholar
• Bryant HU, Glasebrook AL, Yang NN, et al. A pharmacological review of raloxifene. J Bone Miner Metab 1996;14:1–9
   Google Scholar
• Delmas PD, Bjarnasn NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentration, and uterine endometrium in post-menopausal women. N Engl J Med 1997 ;337:1641–7
   PubMed Web of Science ®Google Scholar
• Boss SM, Huster WJ, Neild JA, et al. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997; 177:1458–64
   PubMed Web of Science ®Google Scholar
• Dickler MN, Norton L. The MORE trial: multiple outcomes for raloxifene evaluation — breast cancer as a secondary endpoint: implications for prevention. Ann NY Acad Sci 2001;949:134–42
   PubMed Web of Science ®Google Scholar
• Grodishar WJ. The effect of raloxifene on the risk of breast cancer in post menopausal women. 20th Ameri-can San Antonio Breast Cancer Symposium, San Antonio, Texas, December 1997
   Google Scholar
• Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. AmJ Metab Acad 1999;281:2189–97
   PubMed Web of Science ®Google Scholar
• Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. Am J Metab Acad 1998;279:1445–51
   PubMed Web of Science ®Google Scholar
• Simoncini T, Genazzani AR. Direct vascular effects of estrogens and selective estrogen receptor modulators. Curr Opin Obstet Gynecol 2000;12:181–7
   PubMed Web of Science ®Google Scholar
• Simoncini T, Genazzani AR. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 2000;85:2966–9
   PubMed Web of Science ®Google Scholar
• Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase acti-vation by the selective estrogen receptor modulator raloxifene. Circulation 2002;105:1368–73
   Google Scholar
• Saitta A, Altavilla D, Cucinotta D, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmeno-pausal women. Arteriosder Thromb Vasc Biol 2001;21: 1512–19
   PubMed Web of Science ®Google Scholar
• Zhou W, Koldzic-Zivanovic N, Clarke CH, et al. Selective estrogen receptor modulator effects in rat brain. Neuroendocrinology 2002;75:24–33
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Bernardi F, Stomati M, et al. Effects of estradiol and raloxifene analog on brain, adrenal and serum allopregnanolone content in fertile and ovari-ectomized rats. Neuroendocrinology 2000;72:162–70
   PubMed Web of Science ®Google Scholar
• Nilsen J, Naftolin F. Raloxifene induces neurite out-growth in estrogen receptor positive PC12 cells. Menopause 1998;5:211–16
   PubMed Web of Science ®Google Scholar
• Stomati M, Bersi C, Rubino S, et al. Neuro endocrine effects of different estradiol—progestin regimens in postmenopausal women. Maturitas 1997;28:127–35
   PubMed Web of Science ®Google Scholar
• Neele SJ, Evertz R, Genazzani AR, et al. Raloxifene treatment increases plasma levels of 13-endorphin in postmenopausal women: a randomized, placebo-controled study. Fertil Steril 2002;77:1110–17
   PubMed Web of Science ®Google Scholar
• Florio P, Quirici B, Casarosa E, et al. Neuroendocrine effects of raloxifene hydrochloride in postmenopausal women. Gynecol Endocrinol 2001;15: 359–66
   PubMed Web of Science ®Google Scholar
• Labrie F, Belanger A, Cusan L, et al. Marked decline in serum concentration of adrenal C-19 sex steroid precursors and conjugated androgen metabolites during ageing. J Clin Endocrinol Metab 1997;82: 2396–402
   PubMed Web of Science ®Google Scholar
• Akamatsu T, Chiba H, Kamiyama H, et al. Meno-pause related changes of adrenocortical steroid pro-duction. Asia OceaniaJ Obstet Gynaecol1992;18:271–6
   PubMedGoogle Scholar
• Genazzani AR, Petraglia F, Bernardi F, et al. Circu-lating levels of allopregnanolone in humans: gender, age and endocrine influences. J Clin Endocrinol Metab 1998;83:2099–103
   PubMed Web of Science ®Google Scholar
• Chowen JA, Argente J, Vician L, et al. Pro-opiomelanocortin messenger RNA in hypothalamic neurons is increased by testosterone through aromatization to estradiol. Neuroendocrinology 1990; 52:581–8
   PubMed Web of Science ®Google Scholar
• Cheung S, Hammer RP. Gonadal steroids hormone regulation of pro-opiomelanocortin gene expression in arcuate neurons that innervate the medial preoptic area of the rat. Neuroendocrinology 1995;62:283–92
   PubMed Web of Science ®Google Scholar
• Albrencht ED, Pepe GJ. Effect of estrogen on dehydroepiandrosterone formation by baboon fetal adrenal cells in vitro. Am J Obstet Gynecol 1987;156: 1275–8
   PubMed Web of Science ®Google Scholar
• Hirst JJ, West NB, Brenner RM, et al. Steroid hormone receptors in the adrenal glands of fetal and adult rhesus monkeys. J Clin Endocrinol Metab 1992;75:3078–84
   Web of Science ®Google Scholar
• Casson PR, Elkind-Hirsch KE, Buster JE, et al. Effect of postmenopausal estrogen replacement on circulat-ing androgens. Obstet Gynecol 1997;90:995–8
   PubMed Web of Science ®Google Scholar
• Simon J, Klaiber E, Wiita B, et al. Differential effects ofestrogen—androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmeno-pausal women. Menopause 1999;6:138–46
   PubMed Web of Science ®Google Scholar
• Kraemer RR, Synovitz LB, Gimpel T, et al. Effect of estrogen on serum DHEA in younger and older women and the relationship of DHEA to adiposity and gender. Metabolism 2001;50:488–93
   PubMed Web of Science ®Google Scholar
• Lobo RA, Gobelsmann U, Brenner PF, et al. The effect of estrogen on adrenal androgens in oophor-ectomized women. Am J Obstet Gynecol 1982;142: 471–8
   PubMed Web of Science ®Google Scholar
• Fonseca E, Basurto L, Velasquez S, et al. Hormone replacement therapy increases ACTH/DHEA-S in postmenopause. Maturitas 2001;39:57–62
   PubMed Web of Science ®Google Scholar
• Bernardi F, Pieri M, Stomati M, et al. Circulating allopregnanolone and DHEA levels in postmeno-pausal women under various hormonal replacement therapies. Gynecol Endocrinol 2003;17:65–78
   PubMed Web of Science ®Google Scholar
• Cauley JA, Lucas FL, Kuller LH, et al. Elevated serum estradiol and testosterone concentrations are associ-ated with high risk of breast cancer. Ann Intern Med 1999;130:270–7
   PubMed Web of Science ®Google Scholar